Lots of details, but IMO cash is going to be a problem moving forward, especially with the present FDA trial and Thyroid looming large.
MD&A:
From P7: Typical wording to obfuscate the reality. IMO "something" did happen at JPM even though the markets continue to say not.
January 2023: We attended the J.P. Morgan 41st Annual Healthcare Conference in San Francisco, CA (JPM) and engaged with pharma and biotech companies during the BIO Partnering sessions and other corporate meetings. We also met with and provided a corporate update to analysts and bankers as well as current and potential US investors during LifeSci Partners’ 12th Annual Corporate Access Event hosted concurrently at JPM.
From P24 on "CC": {This may be viewed as a work in progress still. Scale up is important and suggests any residual work is small. My take is CC works in the lab. IMO How they get it to the next stage is the problem.}
Our R&D group has been working closely with Dr. Tomei’s team to advance the collaboration as well as the scale up processes to manufacture sufficient coated cells for clinical applications. We have substantially increased our knowledge regarding the combination of conformally coated islets in the Cell Pouch and have gathered important information about the criteria needed to release the combined product for clinical use.
